Get the Stockscreener App
0.1501
7.46%
-0.0121
Quince Therapeutics Inc stock is traded at $0.1501, with a volume of 21.24M.
It is down -7.46% in the last 24 hours and down -95.61% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$0.1622
Open:
$0.1517
24h Volume:
21.24M
Relative Volume:
0.46
Market Cap:
$8.36M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-0.1787
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
-24.95%
1M Performance:
-95.61%
6M Performance:
-90.79%
1Y Performance:
-89.65%
1-Day Range:
$0.15
$0.1667
1-Week Range:
$0.15
$0.2372
52-Week Range:
$0.1251
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.1501 | 9.03M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
What Does the Market Think About Quince Therapeutics Inc? - Benzinga
Can Quince Therapeutics Inc. stock surprise with earnings upsideJuly 2025 WrapUp & Consistent Return Investment Signals - mfd.ru
Published on: 2026-02-20 10:05:26 - mfd.ru
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Sahm
Market Overview: What is the long term forecast for Warner Music Group Corp stock2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
Quince Therapeutics stock plunges as filing shows reverse merger plans, bankruptcy risks - MSN
What sparked Quince Therapeutics (QNCX) stock to rise 53% after hours - MSN
Sell Signal: Is now the right time to enter Quince Therapeutics IncEarnings Overview Report & Smart Money Movement Tracker - baoquankhu1.vn
Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm
3 Penny Stocks to Watch Now, 2/13/26 - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Quince Therapeutics engages LifeSci Capital for strategic alternatives - marketscreener.com
Quince Therapeutics Inc (QNCX) Stock Price, Quote, News & History - Benzinga
Quince Therapeutics stock plummets after revealing strategic alternatives By Investing.com - Investing.com India
Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com
Quince TherapeuticsOn Feb 9, Engaged Lifesci Capital For Strategic AlternativesSEC Filing - TradingView
Best Penny Stocks To Watch Now – February 10th - Defense World
Small Cap Stocks To Follow Now – February 10th - Defense World
Does Quince Therapeutics Inc. align with a passive investing strategyTrade Entry Summary & Free Weekly Watchlist of Top Performers - mfd.ru
Quince Therapeutics Stock Extends Rally On Strategic Review - Benzinga
Quince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors Emerge - MEXC
Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Alternative Plans - parameter.io
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
QNCX Stock Price and Chart — NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Stock: What’s Behind the 300% Rally? - CoinCentral
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive - TechStock²
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
Why is Quince Therapeutics stock soaring Tuesday? - MSN
QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Mena FN
Why Is Quince Therapeutics Stock Soaring Tuesday? - Benzinga
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock²
Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - PharmiWeb.com
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor By Investing.com - Investing.com Nigeria
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com
Fed Meeting: What is Quince Therapeutics Incs debt to equity ratio2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Quince Therapeutics Announces Significant Board of Directors Resignations - The Globe and Mail
Quince stock plunges 95% following failed clinical trial for inherited childhood disease - The Business Journals
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):